Testosterone enanthate is a Small Molecule owned by Halozyme Therapeutics, and is involved in 6 clinical trials, of which 5 were completed, and 1 is planned.

Testosterone enanthate acts by hormone replacement. TRT (testosterone replacement therapy) increases testosterone levels to normal levels. Testosterone deficiency (TD) results in hypogonadism in which sex glands produce little or no hormones. Free testosterone enters into the cytoplasm of target tissue cells, where it binds to the androgen receptor, or it is reduced by the enzyme 5a-reductase, present in the cytoplasm to 5a-dihydrotestosterone (DHT). Furthermore, testosterone can produce estrogenic effects as a result of its conversion to estrogen.

The revenue for Testosterone enanthate is expected to reach a total of $3.5bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Testosterone enanthate NPV Report.

Testosterone enanthate is currently owned by Halozyme Therapeutics. Antares Pharma is the other company associated in development or marketing of Testosterone enanthate.

Testosterone enanthate Overview

Testosterone enanthate (Xyosted) is a oxoandrosten derivative, acts as an potent androgenic steroid. It is formulated as injectable solution for subcutaneous route of administration. Xyosted indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of  endogenous testosterone like primary hypogonadism (congenital or acquired) and hypogonadotropic hypogonadism (congenital or acquired).

Testosterone enanthate (Xyosted) is under development for male hypogonadism. It is administered through a subcutaneous route. The drug candidate is the combination product that consists of testosterone and our next generation Vibex QS auto injector. It is an auto-injector designed to enhance the injection performance of complex and difficult to inject viscous medicines such as testosterone. It is developed based on the VIBEX technology platform.

Antares Pharma Overview

Antares Pharma is a specialty pharmaceutical company engaged in the development, manufacturing, and commercialization of pharmaceutical products and technologies. The company’s portfolio encompasses around novel therapeutic products for therapy areas related to polyarticular juvenile idiopathic arthritis, severe rheumatoid arthritis, severe recalcitrant psoriasis, migraine and cluster headache. It also develops products to reduce the risk of preterm birth in pregnant women. It caters its subcutaneous injection technology platforms to both generic and branded injectables. Antares Pharma’s injectables are available in disposable multi-dose pen injectors and unit dose containers. The company employs drug delivery systems to advance drug compounds and drug delivery methods. It also focuses on product development programs in partnership with various pharmaceutical companies including Teva Pharmaceutical Industries Ltd, Ferring Pharmaceuticals and AMAG. The company has presence in the US and Switzerland. Antares Pharma is headquartered in Mercer, New Jersey, the US. Antares Pharma is a specialty pharmaceutical company engaged in the development, manufacturing, and commercialization of pharmaceutical products and technologies. The company’s portfolio encompasses around novel therapeutic products for therapy areas related to polyarticular juvenile idiopathic arthritis, severe rheumatoid arthritis, severe recalcitrant psoriasis, migraine and cluster headache. It also develops products to reduce the risk of preterm birth in pregnant women. It caters its subcutaneous injection technology platforms to both generic and branded injectables. Antares Pharma’s injectables are available in disposable multi-dose pen injectors and unit dose containers. The company employs drug delivery systems to advance drug compounds and drug delivery methods. It also focuses on product development programs in partnership with various pharmaceutical companies including Teva Pharmaceutical Industries Ltd, Ferring Pharmaceuticals and AMAG. The company has presence in the US and Switzerland. Antares Pharma is headquartered in Mercer, New Jersey, the US.

Quick View – Testosterone enanthate

Report Segments
  • Innovator (Non-NME)
Drug Name
  • Testosterone enanthate
Administration Pathway
  • Subcutaneous
Therapeutic Areas
  • Male Health
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.